Enveric Biosciences, a biotechnology company developing neuroplastogenic small-molecule therapies for psychiatric and neurological disorders, has announced that it received a US patent for mental health drug candidate EB-003.

 

Entitled “N-heterocycle substituted tryptamine derivatives and methods of using,” the patent protects chemical compounds, pharmaceutical formulations, and methods for treating neurological disorders. 

 

It expands Enveric’s existing patent portfolio and reinforces the company’s claim coverage for its non-hallucinogenic neuroplastogens designed to address neuropsychiatric and addiction disorders.

 

“We are very pleased with this new U.S. patent issuance as we continue to work diligently to reinforce our EVM301 Series intellectual property estate and generate additional value for Enveric stockholders,” said Joseph Tucker, Director and CEO of Enveric. “Our company remains focused on advancing EB-003 towards submitting an IND application to the FDA and initiating a first-in-human Phase 1 clinical trial.”

 

EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes and potentially treat depression and anxiety without hallucinogenic effects. 

 

Enveric’s pipeline is supported by a robust patent estate, comprising 27 issued US patents and roughly 60 pending national and international applications covering multiple differentiated molecules.